PARIS, Feb. 06, 2017 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting calendar for 2017.
Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.
|- 2016 Full-Year Results||March 16, 2017|
|- Shareholders’ AGM||April 25, 2017|
|- 2017 Half-Year results||October 20, 2017|
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
CONTACT: Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 firstname.lastname@example.org LIFESCI ADVISORS- Investor Relations / Financial Communications – Chris Maggos email@example.com